Prevention of community-acquired pneumonia among a cohort of hospitalized elderly

Benefit due to influenza and pneumococcal vaccination not demonstrated

Susan Anne Skull, Ross Andrews, G Byrnes, H Kelly, Terry Nolan, Graham Brown, Donald Campbell

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly ?65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95%CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95%CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting. � 2007 Elsevier Ltd. All rights reserved.
    Original languageEnglish
    Pages (from-to)4631-4640
    Number of pages10
    JournalVaccine
    Volume25
    Issue number23
    Publication statusPublished - 2007

    Fingerprint

    influenza
    Human Influenza
    pneumonia
    Pneumonia
    Vaccination
    vaccination
    vaccines
    Influenza Vaccines
    Hospitalization
    Vaccines
    Pneumococcal Vaccines
    International Classification of Diseases
    Multivariate Analysis
    funding
    multivariate analysis
    polysaccharides

    Cite this

    Skull, Susan Anne ; Andrews, Ross ; Byrnes, G ; Kelly, H ; Nolan, Terry ; Brown, Graham ; Campbell, Donald. / Prevention of community-acquired pneumonia among a cohort of hospitalized elderly : Benefit due to influenza and pneumococcal vaccination not demonstrated. In: Vaccine. 2007 ; Vol. 25, No. 23. pp. 4631-4640.
    @article{b5c093a2c70e42c996f09767aaf6fe84,
    title = "Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: Benefit due to influenza and pneumococcal vaccination not demonstrated",
    abstract = "Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly ?65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95{\%}CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95{\%}CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting. � 2007 Elsevier Ltd. All rights reserved.",
    keywords = "influenza vaccine, pneumococcal polysaccharide vaccine, Pneumococcus vaccine, unclassified drug, aged, article, Australia, clinical effectiveness, cohort analysis, combination chemotherapy, community acquired pneumonia, controlled study, elderly care, female, health care personnel, hospitalization, human, influenza, logistic regression analysis, major clinical study, male, medical documentation, monotherapy, multivariate analysis, priority journal, prophylaxis, random sample, Streptococcus infection, vaccination, Aged, Cohort Studies, Community-Acquired Infections, Female, Hospitalization, Humans, Influenza Vaccines, Male, Pneumococcal Vaccines, Pneumonia, Vaccination",
    author = "Skull, {Susan Anne} and Ross Andrews and G Byrnes and H Kelly and Terry Nolan and Graham Brown and Donald Campbell",
    year = "2007",
    language = "English",
    volume = "25",
    pages = "4631--4640",
    journal = "Vaccine",
    issn = "0264-410X",
    publisher = "Elsevier",
    number = "23",

    }

    Prevention of community-acquired pneumonia among a cohort of hospitalized elderly : Benefit due to influenza and pneumococcal vaccination not demonstrated. / Skull, Susan Anne; Andrews, Ross; Byrnes, G; Kelly, H; Nolan, Terry; Brown, Graham; Campbell, Donald.

    In: Vaccine, Vol. 25, No. 23, 2007, p. 4631-4640.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Prevention of community-acquired pneumonia among a cohort of hospitalized elderly

    T2 - Benefit due to influenza and pneumococcal vaccination not demonstrated

    AU - Skull, Susan Anne

    AU - Andrews, Ross

    AU - Byrnes, G

    AU - Kelly, H

    AU - Nolan, Terry

    AU - Brown, Graham

    AU - Campbell, Donald

    PY - 2007

    Y1 - 2007

    N2 - Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly ?65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95%CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95%CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting. � 2007 Elsevier Ltd. All rights reserved.

    AB - Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly ?65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95%CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95%CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting. � 2007 Elsevier Ltd. All rights reserved.

    KW - influenza vaccine

    KW - pneumococcal polysaccharide vaccine

    KW - Pneumococcus vaccine

    KW - unclassified drug

    KW - aged

    KW - article

    KW - Australia

    KW - clinical effectiveness

    KW - cohort analysis

    KW - combination chemotherapy

    KW - community acquired pneumonia

    KW - controlled study

    KW - elderly care

    KW - female

    KW - health care personnel

    KW - hospitalization

    KW - human

    KW - influenza

    KW - logistic regression analysis

    KW - major clinical study

    KW - male

    KW - medical documentation

    KW - monotherapy

    KW - multivariate analysis

    KW - priority journal

    KW - prophylaxis

    KW - random sample

    KW - Streptococcus infection

    KW - vaccination

    KW - Aged

    KW - Cohort Studies

    KW - Community-Acquired Infections

    KW - Female

    KW - Hospitalization

    KW - Humans

    KW - Influenza Vaccines

    KW - Male

    KW - Pneumococcal Vaccines

    KW - Pneumonia

    KW - Vaccination

    UR - http://www.scopus.com/inward/record.url?scp=34248382167&partnerID=8YFLogxK

    M3 - Article

    VL - 25

    SP - 4631

    EP - 4640

    JO - Vaccine

    JF - Vaccine

    SN - 0264-410X

    IS - 23

    ER -